title: [Adverse effects of statins].
abstract: The safety of the hydroxymethyl glutaryl-coenzyme A reductase inhibitors (statins) has been called into question following the recent withdrawal from the market of one of the class, cerivastatin. The withdrawal of cerivastatin highlighted concerns regarding the safety of the entire class. According to data from several large clinical trials, the statins (except cerivastatin) are well tolerated. The most important and clinically relevant adverse effect reported with statins is myopathy. Myopathy is a clinical diagnosis of elevated creatine phosphokinase and/or myalgia along with fatigue. However, the severe from (i.e. statin-associated rhabdomyolysis) is an uncommon syndrome and occurs at a rate of approximately 1/100,000 patients/years. Statin-associated myopathy is related to statin doses, and often to drug/drug interactions. Other clinically relevant adverse effects associated with statin therapy include liver transminases elevation, which is relatively mild and often self-limiting There is no evidence from clinical trials of a significant alteration of ophthalmological function with statins. The issue of statin-induced cancer remains inconclusive. Overall, the statins seem to exhibit a favourable risk/benefit ratio, and this undoubtedly justifies life-long clinical use of statins for cardiovascular prevention.
authors.affiliation: Service de Pharmacologie Clinique, Hôpital Sud, avenue R. Laënec Salouel, CHU Amiens, 80054 Amiens, France. andrejak.michel@chu-amiens.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Andréjak
authors.forename: Valérie
authors.initials: V
authors.lastname: Gras
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Massy
authors.forename: Jacques
authors.initials: J
authors.lastname: Caron
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced / Q000473:pathology; D011725:Pyridines / Q000009:adverse effects
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin